Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa
May 07 2024 - 8:45AM
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt:
8CT) (the “Company or Cannabix”) developer of alcohol and marijuana
breathalyzer screening devices announces the launch of its new
Breath Logix Workplace Series -Alcohol breath detection device. The
Workplace Series is an autonomous compact wall mounted unit that is
designed for indoor facilities and offices (Figure 1). The Breath
Logix Workplace Series is the newest device within the Breath Logix
series of autonomous alcohol screen devices. Compared to the Breath
Logix Industrial Series, the Workplace Series provides a smaller,
lighter design that is suitable for a range of workplace and
commercial environments. The Company also reports that it has
commenced discussions with Run Rite Electronics Pty Ltd of Durban,
South Africa for the potential sales distribution of the Company’s
new Breath Logix Workplace Series. The Company expects to deliver
its device for evaluation, preliminary marketing and business
development purposes in May.
Justin Goldblatt, Managing Director of Run Rite Electronics
stated, “We really like the compact size of the Breath Logix
Workplace Series for existing and new customers in our market. A
smaller, elegant wall mounted alcohol breathalyzer with integration
capabilities is of particular interest to us. Based in South
Africa, we have business relationships across the continent.”
Figure 1. New Breath Logix Workplace Series
device (left), compared to the Breath Logix Industrial Series
(right).
Breath Logix Workplace Series
Features
The Breath Logix Workplace Series has a sleek, compact design
with a host of features including patent pending pre-calibrated
cartridge technology which will allow site safety administrators to
easily maintain their devices, and eliminate the need for costly
calibration equipment and time-consuming site visits from
technicians for maintenance. This device can be used for pre-access
alcohol testing, random testing, start-of-shift testing,
pre-employment testing, return-to-work testing and post-incident
testing. The technology promotes organizational safety and works to
reduce accidents linked to alcohol consumption.
The Breath Logix Alcohol device automatically checks the
sobriety of a user and can take a picture to confirm and record
identity while a breath sample is being delivered. Upon detection
of positive breath alcohol result, the device will deliver a
precise Blood Alcohol Content (BAC) level on the screen, and send a
real-time alert via text message, e-mail and to a dedicated web
portal. Furthermore, the system logs user BAC for incident
reporting and historical investigations. The Breath Logix helps
organizations save money by deploying an autonomous alcohol
screening device which eliminates the need for dedicated alcohol
screening administrators using conventional handheld devices. There
is no assurance that evaluators of the Company’s breathalyzer
technology will come to terms on distribution or enter into a sales
agreement with the Company.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and
alcohol breathalyzer technologies for law enforcement, workplaces
and laboratories. Cannabix is developing delta-9 THC and alcohol
screening devices. Delta-9 THC is the psychoactive component of
marijuana that causes impairment. Breath testing for delta-9 THC
would allow employers and law enforcement to identify recent
marijuana use. Cannabix is the developer of Breath Logix Series of
autonomous breath alcohol detection devices for employers and a
range of other settings.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEOCannabix Technologies Inc.
For further information, contact the Company
at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that
involves various risks and uncertainties regarding future events.
Such forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that its development of
breathalyzer technology will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. There is no
assurance that evaluators of the Company’s breathalyzer technology
will agree or come to terms on distribution or enter into a sales
agreement, of any kind. There is no assurance that existing “patent
pending” technologies licensed by the Company will receive patent
status by regulatory authorities. The Company is not currently
selling commercial breathalyzers. Actual results and future events
could differ materially from those anticipated in such information.
These and all subsequent written and oral forward-looking
information are based on estimates and opinions of management on
the dates they are made and are expressly qualified in their
entirety by this notice. Except as required by law, the Company
does not intend to update these forward-looking statements.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/3abe2a1a-db95-411b-95fc-643746c2d93b
Cannabix Technologies (TG:8CT)
Historical Stock Chart
From Dec 2024 to Jan 2025
Cannabix Technologies (TG:8CT)
Historical Stock Chart
From Jan 2024 to Jan 2025